SCIENTIA MEETINGS

VACCINES 2026

PROGRAM

EXHIBITORS

enevoyager

IBT BIOSERVICES

DesertKing

VACCINES SUMMIT-2026

November 16-18, 2026
BOSTON, USA

SCIENTIA MEETINGS
Website: https://scientiameetings.com/conferences/vaccines/ | Ph: 1-815-595-8049 | Email: venky@sciresgroup.net

About Organizer:

Welcome to Scientia Meetings, your gateway to excellence in the world of vaccines and cutting-edge healthcare solutions. Over the past three years, we have been at the forefront of organizing successful Vaccines Summit that bring together industry leaders, professionals, and visionaries to foster innovation, collaboration, and business growth.

About Vaccines Summit-2026:

Scientia Meetings invites participants across the globe to attend its fourth edition of Vaccines Summit which is going to take place during November 16-18, 2026, and is organized around the theme “next-generation vaccines treatment and diagnostics that save lives”, Vaccines Summit-2026 is comprised of various sessions designed to offer comprehensive symposiums that address current issues in the field of vaccine research and provides a fantastic opportunity to network with your peers from academia and industry.

Corporate Partnering: Vaccines Summit-2026 help commercialize your innovations and build your business development pipeline through corporate partnering. We will arrange a one-on-one partnering meeting on request. We will share the conference attendees list with you, a month before the conference and arrange for one-on-one meetings with selected corporate representatives.

How does this conference help young scientists? Vaccines Summit-2026 not only opens doors to your career, but also opens your eyes to future opportunities, new cultures, and international perspectives. With the majority of the students interested in doing higher studies abroad, the students’ marketing forum provides an opportunity for Postgraduate and Undergraduate students to have formal communication with University representatives from around the world. Postgraduate student recruitment is increasingly becoming a strategic priority for higher education institutions. Vaccines Summit-2026 provides an excellent networking opportunity for potential collaboration with businesses and organizations for students.

Investment opportunities: Industry prospectors are looking for breakthrough technologies that are ready for licensing, corporate partnering, or investment opportunities. This can include prototypes, demonstrations, and display booths to showcase your innovative solutions at Vaccines Summit-2026. Pitch your idea to an industrial expert jury to raise the capital you need to get started.

Hify-Bac®: A Next-Generation Baculovirus Platform for Vaccine Development and Manufacturing

Advantages of the Sf9/Bac System

- Excellent biosafety profile
- Tolerant of potentially toxic
- Strong VLP assembly capability
- Efficient expression of complex viral antigens
- Rapid development timeline
- Established regulatory precedent & Commercial track record
- Enhanced immunogenicity

Genevoyager Hify-Bac®: Solve the Conventional Challenges of Bac Expression

Overcoming the traditional limitations of baculovirus expression through ***enhanced stability, productivity, and immunogenicity.***

Genetic Stability


- Enhanced baculovirus genetic stability
- Reduced transgene loss during amplification
- Consistent expression across multiple passages

Manufacturing Performance

- Reduced batch-to-batch variability
- Significantly improved productivity
- Higher purified antigen yields
- Lower cost per gram of protein

Hepatitis B Therapeutic Vaccine Produced by Genevoyager Hify-Bac® Platform

Clinical Stage Program




Current status: Phase I trial

- Robust antigen-specific cellular immune responses.
- Strong IFN-γ secretion and T-cell activation.

Evaluation of a Therapeutic Vaccine for Prostate Cancer

Clinical Stage Program



Current status: Phase I trial

- Significant tumor suppression and PAP-specific immunity on day 7.
- Genevoyager's Hify-Bac® platform has supported the project into clinical research.

Genevoyager Hify-Bac® combines the proven advantages of the Sf9/Baculovirus platform with proprietary enhancements in baculovirus stability and productivity, enabling robust, scalable, and cost-effective manufacturing of next-generation therapeutic and prophylactic vaccines.

Website LinkedIn

Genevoyager (Wuhan) Co., Ltd.

globalbd@genevoyager.com +1 (215) 205-6963 www.genevoyager.ltd

No. 128 Guanggu 7th Rd, East Lake High-Tech Development Zone, Wuhan, China

Genevoyager Inc, 3675 Market Street, Suite 200, Philadelphia, PA 19104

www.ibtbioservices.com

Contact us at services@ibtbioservices.com
4 Research Court, Suite 300, Rockville, MD 20850


IBT BIOSERVICES

IBT's facility in Rockville, MD includes 13,300 sq ft of laboratory and office space as well as a 2,700 sq ft vivarium. IBT has a multidisciplinary team of scientists with expertise in vaccine design, development, bioanalytics, and in vivo model development.

An integrated experience uniquely tailored to help you develop modern therapeutics


IBT Bioservices is a full service contract research organization (CRO) for all preclinical testing needs for development of vaccines or therapeutics. IBT will also be offering clinical testing services by mid-2024. IBT's mission is to support discovery, screening, and development phases of product development with an array of testing services including cell-based assays, antiviral & antibacterial assays, toxicology assessments, and pharmacokinetics evaluations.

IBT boasts 15+ highly relevant and validated small animal models for infections up to BSL-2 in-house and BSL-3 & BSL-4 models through partners. IBT also specializes in new animal model and custom assay development to address needs of modern therapeutics. In addition to the service capabilities, IBT has a repository of viral and bacterial panels for over 20+ pathogen species and is regularly involved in development of new panels.



With a strong client-oriented approach, IBT has been a pioneer in infectious disease research at the forefront of global public health initiatives since 2005.

Shop our quality reagents from our website or via one of our global distributors for your research or assay development. We produce reagents for a wide range of viral and bacterial targets such as Influenza, Ebola, Marburg, Herpes virus, *Staphylococcus aureus*, SARS-COV2, *Clostridium difficile*, HIV, Chikungunya, Dengue, Zika, *Pseudomonas*, and many more.



ANTIBODY | ELISA KITS | PROTEIN | PSEUDOVIRUS | REPORTER CELLS | VIRUS-LIKE PARTICLES

WHY CHOOSE US?

- Project Management & Quality
- Flexibility & Scalability
- Seemless Collaborations
- Cost-Effective Solutions
- Timely Delivery of Results

IBT provides comprehensive services and concierge-level support, making it your one-stop shop for all your biotherapeutic development needs.

DesertKing®

Leading innovation in saponin-based products and adjuvants for over 30 years.

QS 21

THE HUMAN VACCINE-QUALITY BENCHMARK

About Desert King®

For over **30 years**, Desert King® has been the **global leader in Quillaja saponin–based adjuvants**, recognized for their powerful immunostimulant properties. Our products are used in five approved human vaccines—including **COVID-19, malaria, RSV, and shingles**—by leading manufacturers such as **GSK and Novavax**, as well as in numerous veterinary vaccines.

We are the only Quillaja extract supplier worldwide with FSC® Chain of Custody certification (FSC® C156804), ensuring sustainable and fully traceable sourcing. Our state-of-the-art facility is **EXCiPACT™- certified**, setting a benchmark for pharmaceutical-grade quality, manufacturing excellence, and regulatory compliance.

We provide innovative, science-based adjuvants that support vaccine manufacturers with reliable quality, scalable supply, and products tailored to specific immunological profiles.

QS-21 from Desert King is the human vaccine-quality benchmark



What makes QS-21 so important?

One of the **world's most powerful immunostimulants**, QS-21 is derived from the bark of the **Quillaja saponaria Molina tree** using advanced HPLC separation technology for purification. This particular saponin fraction is **capable of inducing both humoral as well as cell-mediated immunity.**

Contact us at
info@desertking.com
or +1 (619) 429-5222

Day-1 Monday - November 16, 2026

KEYNOTE PRESENTATIONS

Session Chair:
Dan Barouch
Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center

08:00-08:30 

Vaccines in the Era of Artificial Intelligence
Rino Rappuoli
Scientific Director of the Biotecnopolo di Siena Foundation

08:30-08:45 

Transforming Public Research into Strategic Capability for Health Security and Pandemic Preparedness: The Italian Experience
Gianluca Polifrone
Director General of the Fondazione Biotecnopolo di Siena

08:45-09:15 

Beyond conventional vaccination outcomes: Expanding how we investigate vaccine value
Sanjay Gurunathan
Senior Vice President and Global Head, Vaccines and Infectious Disease R&D, GSK

09:15-09:45 

From Reaction to Readiness by Design: Viral Family Framework as a Transformational Engine for Vaccine R&D to secure Speed and Equity
Mandeep Singh Dhingra
Director and Head, R&D Programs, CEPI


09:45-10:15 

Correlates of Protection for Respiratory Pathogen Vaccines
Dan Barouch
Director,
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center

10:15-10:30 Coffee Break Group Photo

10:30-11:00 

A novel OMV-Based Platform Enabling Rapid Vaccine Development for Infectious Diseases and Cancer
Guido Grandi
Senior Professor of Microbiology and Clinical Microbiology, COO, BiOMViS Srl

11:00-11:30 

From Systems Vaccinology to Universal Vaccines
Bali Pulendran
Director, Institute for Immunity,
Transplantation and Infection, Stanford University School of Medicine

SESSION 1: Next-Generation Vaccine Technologies

- **mRNA & self-amplifying RNA (saRNA) platforms**
- **Viral vector & nanoparticle vaccines**
- **Microneedle patches & needle-free delivery**
- **Mucosal/intranasal vaccines**
- **Universal vaccine concepts (influenza, coronavirus)**

Session Chairs:

Antu K. Dey, Vice President, Research & Early Development, Vitrivax Inc

James F. Cummings, Vice President, Chief Medical Officer, Vaxart Biosciences, Inc

11:30-11:50 

Nano Vaccines: Fighting Infection in Humans

Thomas Webster

Past President US Society for Biomaterials


Nominated for the Nobel Prize in Chemistry (2026)

11:50-12:10 

Novel nanoparticle respiratory tract mucosal tuberculosis vaccine

Frederick Quinn

Professor in the College of Veterinary Medicine at the University of Georgia

12:10-12:30 

NYVAC-KC, A Replication Competent, Highly Attenuated Vaccinia Virus Vaccine Vector

Bertram Jacobs

Professor, School of Life Sciences, Arizona State University

12:30-12:50 

Move over plasmid - Synthetic DNA is the future

Kate Broderick

Chief Scientific and Innovation Officer, Artis Biosolutions

12:50-14:00 Lunch Break

14:00-14:20 

Computational Design of a Bivalent Vaccine Against Respiratory Syncytial Virus and Human Metapneumovirus

Taylor Cohen

Global Product Lead, AstraZeneca

14:20-14:40 

PharmaJet – The Global Leader in Needle-Free Jet Injection

Tom Hess

Senior Director, Corporate Development, PharmaJet

14:40-15:00 

Single-dose, thermostable, controlled release novel ALTA® platform technology to improve vaccine immune response

Antu K. Dey

Vice President, Research & Early Development, Vitrivax Inc.

15:00-15:20 

Exploiting molecular mimicry for cancer vaccine development
Luigi Buonaguro
Director of the Innovative Immunological Models at the National Cancer Institute "Pascale ", Naples – Italy.

15:20-15:40 

Ex vivo loaded autologous dendritic cell vaccines for cancer and infectious diseases
Robert O. Dillman
Chief Medical Officer, AIVITA Biomedical, Inc.

15:40-16:00 

Back to the Future: Spray Inactivated Whole Influenza Virus—A Universal Vaccine?
Parker A. Small, Jr
Professor Emeritus, Departments of Pediatrics and Pathology, University of Florida

16:00-16:15 Coffee Break

16:15-16:35 

fuRNAce- RNA manufacturing that matches the speed of therapeutic development
Ian Johnson
Director of Life Sciences, bioforge

16:35-16:55 

Next Generation LNP Technology for Infectious Disease mRNA Vaccines
Ghania Chikh
Senior Director, Vaccine Development, Acuitas Therapeutics

16:55-17:15 

A Century Longing for a Dengue Vaccine – Where Are We and Where are We Going?
Stephen J. Thomas
Infectious Diseases Physician-Scientist, SUNY Upstate Medical University

17:15-17:35 

Broadly neutralizing antibody ligands as non-cognate antigens for Hepatitis C virus-neutralizing antibodies-inducing vaccine
Milan Raska
Palacky University Olomouc, Czech Republic

17:35-17:55 

A Self-Assembling Protein Vaccine Stabilized in Hyaluronic Acid Microneedles Enables Needle-Free Immunotherapy for HPV-Associated Cancer
Yohannes Hailu
Vaccine & Immunotherapy Center, Massachusetts General Hospital

17:55-18:15 

A Single Dose, Room-Temperature Stable Vaccine Platform using Extracellular Vesicles
Christopher P. Locher
CEO and Co-Founder, Versatope Therapeutics

18:15-18:35 

Structure-based Design and Development of Next Generation Respiratory Syncytial Virus (RSV) Vaccine
Lei Chen
Founder and CEO, Yikang Biotech

18:35-18:55 

Intranasal mRNA vaccine: *Targeting the front lines of respiratory virus defense*
Mona Motwani
Sanofi

18:55-19:15 

An adaptable formulation platform enabling thermostability and mucosal delivery across biologic modalities
Tim Obara
Chief Executive Officer, Jurata

19:15-19:35 

A Phase 2, Double-Blind COVID 19 Vaccine Study Comparing Vaxart's Oral Tableted COVID 19 Vaccine to an FDA Approved mRNA Injectable Vaccine – Results From The Sentinel Safety Cohort
James F. Cummings
Chief Medical Officer, Vaxart Biosciences, Inc

19:35-20:35 **POSTER SESSION & RECEPTION**

P-01 

Improving Influenza Vaccine Efficacy Trials by Optimizing Virus Recovery from Suspected Influenza-like Illness Subjects
Brandon F Young
Senior Medical Science Liaison, Mid-Atlantic Region, Medical Affairs, CSL

P-02 

Beyond the Outbreak: Practical Discussion and Partnership Models to Normalize Mpox Vaccination
Biyanka Patel
Sr. US Medical Science Liaison – Northeast Region, Bavarian Nordic Inc.

P-03 


Beyond Antibody Titers: Applying Systems Serology to Accelerate Vaccine Development and Identify Functional Correlates of Risk and Protection
Andrew Ball
Chief Executive Officer, SeromYx

P-04

Defining a role in Trafficking Signals to Modulate Immune Responses in mRNA and Self-Amplifying RNA Tuberculosis
Yu Sun
The Center for Virology and Vaccine Research --Beth Israel Deaconess Medical Center

P-05 

Nanoparticle Platform and Adjuvant Formulation Selection Shape the Magnitude, Breadth, and Epitope Specificity of HIV-1 Env Antibody Responses
Jayeshbhai Chaudhari
The Center for Virology and Vaccine Research --Beth Israel Deaconess Medical Center

P-06 

Mucosal co-administration of NP with HA broadens cross-protective immunity against influenza viruses

Liping Wang
The Center for Virology and Vaccine Research --Beth Israel Deaconess Medical Center

P-07 

From Plasmid to Purified Protein in ~15 Days: The C1 Platform for Rapid Development of Vaccine Antigens and Monoclonal Antibodies Against Emerging Pathogens

Mark Emalfarb
Founder and Chief Executive Officer of Dyadic International, Inc.

P-08 

Unlocking Therapeutic Vaccines with the Hify-Bac® Baculovirus–Sf9 Platform: A High-Fidelity, Scalable System for Complex Antigens and Virus-Like Particles

Xiaobin He
CEO, Genevoyager

Day-2 Tuesday - November 17, 2026

KEYNOTE PRESENTATIONS

Session Chair:
Duccio Medini
Chief Science and Technology Officer, Pitt BioForge, Toscana Life Sciences Foundation, Siena, Italy

08:00-08:30 


The Pathogen We Didn't Expect: Bundibugyo Ebolavirus and the Prototype-Pathogen Approach to Pandemic Preparedness

Nancy Sullivan
Professor of Biology and Virology, Immunology & Microbiology, Boston University

08:30-09:00 

The science of vaccine adjuvants

Derek O'Hagan
Senior Advisor, GSK Vaccines R&D

09:00-09:30 

Rationally Engineered Self-Assembling Protein Nanoparticles for Allergen-Specific Peanut Allergy Immunotherapy

Jiang Zhu
Professor, Integrative Structural and Computational Biology, Immunology and Microbiology, The Scripps Research Institute

09:30-10:00 

High-Resolution 3D-Printed Microneedle Array Patches for Vaccine Delivery and Interstitial Fluid-Based Immune Monitoring

Joseph M. DeSimone
Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering, Co-Director, Canary Center at Stanford University

10:00-10:20 Coffee Break

10:20-10:50 

Five-year Phase II RCT of at-risk diabetic Alzheimer's patients: Impact and mechanism of multi-dose BCG

Denise L Faustman

Director of Immunobiology, Massachusetts General Hospital, Associate Professor Medicine, Harvard Medical School

10:50-11:20 

A Universal AI Design Framework and Brokerage Platform for Democratised Manufacturing of mRNA Therapeutics

Duccio Medini

Chief Science and Technology Officer, Pitt BioForge,
Toscana Life Sciences Foundation, Siena, Italy

11:20-11:50 

Discovery of T cell imprinting for immune readiness

Alessio Lanna

Professore Ordinario, University College London and CEO, Sentcell ltd (UK)

SESSION 2: Coronavirus & Pandemic Preparedness

- **Variant-proof & pan-coronavirus vaccine designs**
- **Transmission-blocking mucosal vaccines**
- **Preparedness for "Disease X"**
- **Rapid manufacturing & outbreak response**
- **COVID-19 booster durability and immune memory**

Session Chair:

Cristina Cassetti

Senior Scientific Advisor to CEPI and WHO

11:50-12:10 

Vaccine R&D for pandemic preparedness and response-research strategies in government, non-profit and WHO

Cristina Cassetti

Senior Technical Advisor, R&D Blueprint, WHO

12:10-12:30 

A general strategy for T cell epitope design

Alessandro Sette

Dr. Biol. Sci. Professor and Member, Co-Director LJI Center for Vaccine Innovation, La Jolla Institute for Immunology

12:30-12:50 

Learning B & T cell immunology from novel vaccine efforts

Shane Crotty

Professor & Chief Scientific Officer (CSO) | La Jolla Institute for Immunology (LJI), Director | LJI Center for Vaccine Innovation

12:50-14:00 Lunch Break

14:00-14:20 

Rapid Microbial Production of Structurally Correct Prefusion Trimers Using the C1 Platform - CHO-like structure and neutralization with gram-per-liter yields in 7 day

Mark Emalfarb

Founder and Chief Executive Officer of Dyadic International, Inc.

14:20-14:40 

Humoral Correlates of Risk for SARS-CoV-2 Breakthrough Infection Following mRNA Vaccination

Lenny Moise

CSO, SeromYx Systems, Inc.

14:40-15:00 

Building the Preparedness Industrial Base: Connecting Innovation, Manufacturing, and National Readiness

Mike Stebbins

Sr. Vice President, Medical & Threat Countermeasures, Advanced Technology International

15:00-15:20 

A cytokine organizing principle programming innate immune defense at the respiratory surface

Daniel Lingwood

Associate Professor of Medicine, Ragon Institute of MGH, Harvard University

15:20-15:40 

Adaptive and innate immune regulation by antibody signaling

Taia T Wang

Associate Professor of Medicine and of Microbiology and Immunology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine

15:40-16:00 Coffee Break

SESSION 3: Clinical Trials, Safety & Regulatory Science

- Adaptive & decentralized trial models
- Immune correlates of protection
- Pharmacovigilance & real-world safety data
- Regulatory harmonization: FDA–EMA–WHO collaborations
- Ethics of emergency use vaccines

SESSION 4: AI & Computational Tools in Vaccine Research

- AI-driven antigen discovery
- Machine learning in trial design & safety prediction
- Computational immunology & digital twins
- Reverse vaccinology 3.0
- AI for quality control & manufacturing optimization

Session Chair:

Laura E. Carreto-Binaghi

Center for Vaccine Development and Global Health, University of Maryland School of Medicine

16:00-16:20 

Vaccines at a Crossroads: Precision Vaccines as a New Paradigm

Ofer Levy

Director, Precision Vaccines Program, Boston Children's Hospital

16:20-16:40 

Vaccine off-target effects and implications for clinical trial design
Asimenia Angelidou
Clinical Lead, Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital

16:40-17:00 

Beyond Infectious Disease: A Vaccine Against a Drug of Addiction
Seth Toback
Chief Medical Officer, ARMR Sciences

17:00-17:20 


High-dimensional characterization of pre-existing systemic T cellular immune responses to *Salmonella enterica* serovar Typhi in unexposed individuals
Laura E. Carreto-Binaghi
Center for Vaccine Development and Global Health, University of Maryland School of Medicine

17:20-17:40 

AI-powered vaccine antigen discovery for Group A *Streptococcus*
Gry Persson
Senior Project Manager, Infectious Diseases, at Evaxion, Denmark

17:40-18:00 

AI-assisted immunogen design
Jimmy Golihar
Professor of Pathology & Genomic Medicine, Houston Methodist Research Institute

18:00-18:20 

Xenoglycosylation of the HIV-1 Glycan Shield Enhances Vaccine-Induced Neutralizing Antibody Breadth
Jiang Zhu
Professor, Integrative Structural and Computational Biology, Immunology and Microbiology, The Scripps Research Institute

18:20-18:40 

Vaccination generates broadly cross-neutralizing antibodies to the HIV Env spike apex
Richard T Wyatt
Professor, Department of Immunology and Microbiology, The Scripps Research Institute IMM28

Day-3 Wednesday - November 18, 2026

KEYNOTE PRESENTATIONS

Session Chair:
Walter A. Orenstein
Professor Emeritus of Medicine, Epidemiology, Global Health, and Pediatrics, Emory University

08:00-08:30 

Vaccines Don't Save Lives. Vaccinations Save Lives
Walter A. Orenstein
Professor Emeritus of Medicine, Epidemiology, Global Health, and Pediatrics, Emory University

08:30-09:00 

Current Vaccine Realities: Truth or Consequences
Barney S. Graham
Professor of Medicine and Microbiology, Biochemistry, & Immunology, Director of the David Satcher Global Health Equity Institute, Morehouse School of Medicine

09:00-09:30 

Maternal Immunization: Impact and Possibilities
Saad Omer
Dean and Professor Lyda Hill Deanship of the School of Public Health, UT Southwestern O'Donnell School of Public Health

09:30-10:00 

Global Immunization: Developments, Directions, and Decentralization
Lora Shimp
Director - Immunization, at JSI

10:00-10:20 Coffee Break

10:20-10:50 

Mapping the Global Vaccine Ecosystem. Here's What Developers Are Missing
Hansilla Alaigh
CEO, WISE-R

10:50-11:20 

Infant RSV Prevention in LMICs: Lessons from Previous Vaccine Introductions and Considerations for Maternal RSV Immunization,
Kashmira Date
Senior Director, Pfizer

11:20-11:50 

Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts
Pascal Geldsetzer
Assistant Professor of Medicine and, by courtesy, of Epidemiology and Population Health, Stanford University

SESSION 5: Vaccines for Emerging & Neglected Diseases

- **Vaccines for NTDs: dengue, chikungunya, leishmaniasis**
- **Helminth & parasitic vaccine development**
- **One-Health & zoonotic spillover prevention**
- **AMR-targeted bacterial vaccines**
- **Vaccines for low-resource settings (thermostable, low-cost platforms)**

Session Chair:
Stuart M. Levitz
Professor of Medicine and Microbiology at UMass Chan Medical School

11:50-12:10 

A pan-hemorrhagic fever virus vaccine protecing from Sudan-, Marburg- and Lassavirus infection
Ralf Wagner
University Professor, Head of Molecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, Regensburg University

12:10-12:30 

Subunit Cryptococcus Vaccines: Progress and Challenges
Stuart M. Levitz
Professor of Medicine and Microbiology at UMass Chan Medical School

12:30-12:50 

A humanized mouse model to investigate protection by a new tuberculosis vaccine
Luciana C C Leite
Laboratyrio de Desenvolvimento de Vacinas, Instituto Butantan

12:50-14:00 Lunch Break

14:00-14:20 

A vaccine against human cytomegalovirus: what do we target and why?
Matthew Reeves
Professor of Viral Pathogenesis, Course Director MSc Infection & Immunity, Institute of Infection, Immunity & Transplantation, University College London

14:20-14:40 

Development of next-generation live attenuated vaccines against tuberculosis
Akil Akhtar
Staff Scientist, Texas Biomedical Research Institute

14:40-15:00 

Mucosal administration of a nano emulsion based Th17-inducing adjuvant enhances protection against TB in BCG-vaccinated rhesus macaques
Venkata Siva Reddy Devireddy
Postdoctoral Scientist, Texas Biomedical Research Institute

SESSION 6: Conjugate Vaccines & Glycoconjugate Innovations

- **Next-gen glycoconjugate vaccines**
- **Novel carrier proteins & conjugation chemistries**
- **Glycoengineering & synthetic carbohydrates**
- **Conjugate vaccines for AMR pathogens**
- **High-valency pediatric and adult conjugate vaccines**

KEYNOTE PRESENTATION

15:00-15:30 

Glycoengineering immunologically superior conjugate vaccines
Matthew P. DeLisa
Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University

Session Chair:
Matthew P. DeLisa, Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University

15:30-15:50 

VAX-31 Pneumococcal Conjugate Vaccine with 31 serotypes
Patricia Novy
Vice President of Medical Affairs, VAXCYTE

15:50-16:10 

Glycoengineering of the hepatitis C virus envelope protein improves biochemical properties and enhances immunogenicity

Thomas R. Fuerst
Professor, Department of Cell Biology and Molecular Genetics
Director, Center for Glycoengineering of Advanced Biologics, Fellow, Institute for Bioscience and Biotechnology Research, University of Maryland

16:10-16:20 Lunch Break

16:20-16:40 

WISIT - neoglucoconjugate vaccine platform to elicit unprecedented, target-specific antibody responses: enabling novel treatments for chronic diseases

Markus Mandler
Founder & CEO, Tridem Bioscience FlexCo

16:40-17:00 

MAPS Technology - A Next-Generation Vaccine Platform Beyond Traditional Covalent Glycoconjugation

Anup K. Upadhyay
Director, MAPS Protein Sciences, Bacterial Vaccines R&D, GSK

SESSION 7: Vaccine Adjuvants & Immune Modulation

- **Precision adjuvants**
- **Adjuvants for mucosal vaccines**
- **Systems vaccinology for adjuvant discovery**
- **Novel adjuvants for emerging/NTD pathogens**

Session Chair:
Alan Herbert
President and Founder InsideOutBio.com

17:00-17:20 

Lymph node-targeted DNA adjuvants drive strong and durable adaptive immunity via the TBK1/IFN-I axis

Martin Steinbuck
Director of Research, Elicio Therapeutics

17:20-17:40 

Exploiting the Host Cell Z-RNAs Produced During Virus Infections in Vaccine Designs

Alan Herbert
President and Founder InsideOutBio.com

17:40-18:00 

Small Molecule Direction of T Cell Fate in Vaccine Responses: A High-Throughput Discovery Platform

Aaron P. Esser-Kahn
Associate Professor, Pritzker School of Molecular Engineering
University of Chicago

18:00-18:20 

Isolation and characterization of monoclonal antibodies for prevention and treatment of herpes simplex virus (HSV) infections

Aakash Mahant Mahant
Instructor, Albert Einstein College of Medicine

18:20-18:40 

Securing the Future of Saponin Adjuvants: Sustainable QS-21 Supply and Beyond

Zoltan Beck
Senior Director, Adjuvant Strategy & Scientific Affairs, Desert King International

Closing Ceremony & Vote of Thanks

SCIENTIA MEETINGS
VACCINES SUMMIT-2027
November 15-17, 2027 | BOSTON, USA
https://scientiameetings.com/conferences/vaccines/

SCIENTIA MEETINGS

VACCINES 2026

PROGRAM

EXHIBITORS

enevoyager

IBT BIOSERVICES

DesertKing

VACCINES SUMMIT-2026

November 16-18, 2026
BOSTON, USA

SCIENTIA MEETINGS
Website: https://scientiameetings.com/conferences/vaccines/ | Ph: 1-815-595-8049 | Email: venky@sciresgroup.net